Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA Commissioner Admonishes Health Care Stakeholders To Know Agency Better, Help More

Executive Summary

Califf was candid during an FDA Science Board meeting about the agency’s limits, such as disseminating accurate information in response to rampant misinformation during COVID-19 pandemic. “We need to call out people who are outside the FDA … because this vast universe of information out there is way bigger than we can handle on our own,” he said.

You may also be interested in...



Allowing States To Ban Abortion Services Increases Calls For Making Birth Control Available OTC

Supreme Court’s six conservative justices say Constitution doesn’t guarantee a woman’s right to abortion services nor prohibit states from regulating or banning the services. Dissenting liberal members decry decision as erasing women’s constitutional rights.

House Appropriators Reject Docking FDA FY2023 Budget Until Formula Crisis Report Provided

First-term Iowa Republican Hinson had support from Democrat as well as other GOP members for withholding part of commissioner office’s FY2023 budget. Opposition from a self-acknowledged unlikely source, committee chair DeLauro, steered votes toward rejecting the proposal.

CBD Could Be Only Hemp Allowed For Use In Supplements In US, House Appropriators Suggest

Appropriators’ comments provided with FY2023 FDA budget bill suggests agency will resolve dilemma of sales of hemp ingredients in non-drug products by making only CBD lawful.

Topics

Latest News
UsernamePublicRestriction

Register

MT145521

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel